JBC Connect with Cosmo for Collagen Detection

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M513278200 on March 14, 2006

J. Biol. Chem., Vol. 281, Issue 19, 13604-13611, May 12, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
281/19/13604    most recent
M513278200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bai, S.
Right arrow Articles by Jacob, S. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bai, S.
Right arrow Articles by Jacob, S. T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Identification of T-cadherin as a Novel Target of DNA Methyltransferase 3B and Its Role in the Suppression of Nerve Growth Factor-mediated Neurite Outgrowth in PC12 Cells*Formula

Shoumei Bai, Kalpana Ghoshal, and Samson T. Jacob1

From the Department of Molecular and Cellular Biochemistry, College of Medicine, Ohio State University, Columbus, Ohio 43210

Received for publication, December 13, 2005 , and in revised form, March 14, 2006.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Previously we showed that DNA methyltransferase 3b (Dnmt3b) is required for nerve growth factor (NGF)-induced differentiation of PC12 cells to neuronal phenotype. The present study identified T-cadherin (T-Cad) as one of the targets of Dnmt3b by chromatin immunoprecipitation (ChIP) assay. Combined bisulfite restriction analysis and bisulfite sequencing showed that T-Cad promoter was sparsely methylated in PC12 cells. ChIP-CHOP analysis demonstrated that Dnmt3b is associated with T-Cad promoter irrespective of its methylation status. The mRNA and protein levels of T-Cad were markedly elevated in cells depleted of Dnmt3b by antisense or small interfering RNA. Suppression of T-Cad promoter activity by Dnmt3b was independent of its catalytic activity, which was consistent with the insignificant change in T-Cad promoter methylation status in Dnmt3b-depleted cells. In contrast, deletion of its N-terminal ATRX and PWWP domain abolished its repressor function. Association of histone deacetylase 2 (Hdac2) with T-Cad promoter and restoration of the promoter activity from Dnmt3b-mediated suppression upon treatment with Hdac inhibitor indicated involvement of histone deacetylation in this process. NGF-induced neurite outgrowth was inhibited in a dose dependent manner upon ectopic expression of T-Cad in PC12 cells. Immunofluorescence studies showed that T-Cad was redistributed upon NGF treatment, as evident from its concentration in axon growth cones as opposed to its localization at cell-cell contact region in undifferentiated cells. These results demonstrate a novel role of T-Cad in the NGF-mediated differentiation of PC12 cells to neuronal phenotype.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Epigenetic regulation of gene expression is mediated by DNA methylation, post-translational modification of histones and chromatin remodeling. DNA methylation is a unique modification of the eukaryotic genome, which is characterized by selective methylation of cytosine at C-5 of a CpG dinucleotide (1-4). Hypermethylation of the promoter region leads to the docking of methyl C-binding proteins followed by recruitment of specific co-repressors that include histone deacetylases and chromatin remodeling factors (5-9). Formation of a large repressor complex in the promoter region prevents access of the key trans-activating factors to the promoter, which results in transcriptional repression. Many tumor suppressor genes are silenced in a variety of primary human cancer cells by promoter methylation, whereas some oncogenes are activated by hypomethylation (10-13). Altered methylation profile of the genome is a hallmark of cancer (14, 15). DNA methylation is directed by three DNA methyltransferases, namely Dnmt1,2 Dnmt3a, and Dnmt3b. Dnmt3a and Dnmt3b are de novo methyltransferases that initiate the methylation process, whereas Dnmt1, the maintenance methyltransferase, directs methylation of the newly synthesized strand complimentary to the hemimethylated DNA, which occurs concurrently with DNA replication.

Previous study in our laboratory showed a marked increase in the expression of de novo DNA methyltransferase Dnmt3b concurrent with the down-regulation of Dnmt3a and Dnmt1 during differentiation of PC12 cells to neuronal cells induced by NGF (16). Furthermore, the differentiation process was retarded in cells following depletion of endogenous Dnmt3b with antisense Dnmt3b or specific siRNA (16). Surprisingly, the differentiation process did not involve significant alteration in genomewide methylation status, which was confirmed by the lack of requirement of the catalytic domain of Dnmt3b in the NGF-mediated neurite outgrowth. The logical next step was to identify the Dnmt3b target genes and how these genes are regulated. The present study focused on T-Cad, one of the target genes of Dnmt3b, for the following reasons: (a) it is one of the cadherin family of proteins that plays an important role in cell-cell adhesion and cell signaling (17); (b) T-Cad is differentially expressed during embryogenesis (18); (c) it is highly expressed in a subtype of neuronal cells in human central nerve system (19); (d) T-Cad as a substrata inhibits culturing motor neuron axon growth (20); and (e) it is known to be targeted for promoter DNA methylation (21, 22).

T-Cad or truncated cadherin lacks the transmembrane region and the cytoplasmic domain that is required for the binding of beta-catenin, an important factor involved in cadherin-mediated cell-cell adhesion. T-Cad appears to play an important role in maintaining cell-specific phenotype. Methylation followed by silencing of T-Cad is often observed in colorectal breast and lung cancers (21, 23). Hypermethylation of T-Cad is associated with poor prognosis of cervical cancer (24). It is expressed in different neuronal populations and is regulated in a temporally and spatially restricted pattern during motor axon growth. This protein is discretely distributed in the region devoid of growth cone (19), which suggests a potential role of T-Cad in the regulation of neurite outgrowth. These data have been further substantiated in cell culture condition, where T-Cad blocks neurite extension of spinal motor neurons both as a substratum and as a soluble recombinant protein (20). A high T-Cad level is also found in cardiac and vascular tissues where aryl hydrocarbon receptor ligands can repress its expression. T-Cad is co-segregated with signaling molecules such as G-protein and SRC family kinase, which implicates its role as an intracellular signaling molecule (25). Interestingly, T-Cad can also function as a receptor for low density lipoprotein and adiponection/Acrp30 (26, 27). T-Cad is down-regulated by growth factors such as IGF, EGF, and bDGF in smooth muscle cells (28). The molecular mechanism for its down-regulation by these growth factors has not been elucidated. The identification of T-Cad as one of the target genes of DNA methyltransferase 3b coupled with increased expression of this DNA methyltransferase during differentiation of PC12 cells provided an important experimental system to study the function of T-Cad in the differentiation process. The present study addresses the mechanism by which Dnmt3b suppresses T-Cad expression and the role of T-Cad in NGF-induced differentiation of PC12 cells.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents and Antibodies—Trichostatin A (TSA) was from Sigma. NGF was from Roche Applied Science. Anti Dnmt3b antibody was raised in our laboratory as described previously (29). Anti-T-Cad and anti-HDAC2 antibodies were from Santa Cruz Biotechnology. Anti-MYC and anti-FLAG (M2) antibodies were from Sigma and anti-Ku-70 antibody (N3H10) was from Neomarker.

Cell Line and Tissue Culture—PC12 cells were cultured and treated with NGF as described earlier (16).

Construction of Plasmids and Generation of Stable Cell Lines—T-Cad-FLAG (T-CadFLAG): T-Cad cDNA was amplified from mouse lung cDNA library (primers 5'-CGG GAT CCC TTC TAG TCG GGC AAG ATG CA, and 5'-CGG AAT CCT CAC AGA CCT GAC AAT AAG CTG A). The PCR product was phosphorylated and ligated to the EcoRV site of pcDNA3.1(-) to generate T-Cad-pcDNA3. The authenticity of the clone was verified by sequencing. Next, T-Cad was PCR-amplified from T-Cad-pcDNA3 with the same forward primer and 5'-CGGGATCCCAGACCTGACAATAAGCTGA as the reverse primer digested with BamHI and was cloned into the same site of pCMV-3xFLAG (Sigma) to generate T-CadFLAG. To obtain T-Cad-expressing cells, T-CadFLAG was transfected into PC12 cells and selected with G418 (500 µg/ml). Expression of T-Cad in stable cell lines was verified by Western blot analysis with anti-FLAG M2 antibody.

T-Cad Promoter-Luciferase Reporter Gene (pT-CadGL2)—T-Cad promoter was PCR-amplified from PC12 cell genomic DNA with primers 5'-CGG GGT ACC CAG AGT CTG GGC AAC ATG CTG T and 5'-CCG CTC GAG TGC GGC TCA CAT TCC CTA CCTG and cloned into the KpnI and XhoI site of pGL2 basic plasmid (Promega).

Dnmt3b-{Delta}PWWP—PWWP domain deletion mutant of Dnmt3b was generated by PCR as described earlier (16) with the primers 5'-GG GGT ACC ACC ATG ATC TCT GCT GAC AAA CTG GTG and 5'-CG GGA TCC TTC ACA GGC AAA GTA GTC CTT. The PCR product was cloned into KpnI and BamHI sites of pCMV-3xFLAG (Sigma).

Western Blot Analysis—Cellular proteins were extracted with cell lysis buffer (50 mM Tris-HCl, pH 7.5, 10% glycerol, 2% SDS, and 1 mM dithiothreitol) or as indicated. The extract was resolved by SDS-PAGE, transferred to the nitrocellulose membrane, and subjected to immunoblot analysis.

Real-time Quantitative RT-PCR and RT-PCR—Total RNA was isolated from PC12 cells using acid guanidinium thiocyanate-phenol method (30) and was treated with Turbo DNase 1 (Ambion) following manufacturer's protocol. cDNA was synthesized from 1 µg of total RNA using random hexamers as primers and murine leukemia virus reverse transcriptase following the manufacturer's protocol (Applied Biosystem). An aliquot of the cDNA (equivalent to 100 ng of RNA T-Cad and 2 ng for 18 S rRNA) was used for real-time PCR analysis. All reactions were carried out using the Mx3000 Multiplex quantitative PCR system (Stratagene) as described previously (16). The PCR primers used for RT-PCR analysis were 5'-AAA CCT CAG CGT GGT CAT CCT and 5'-GCG TGG GTG TTG TTG ATT TTG for amplification of T-Cad and TCA AGA ACG AAA GTC GGA GG and GGA CAT CTA AGG GCA TCA CA for 18 S rRNA. RT-PCR analysis of Dnmt3b and COX-1 (cytochrome c oxidase) was as described previously (16).

COBRA and Bisulfite Genomic Sequencing—Cells were treated with bisulfite reagent as described (31). T-Cad CpG island (CGI) located at proximal promoter and exon 1 was amplified by nested PCR with primer set #1 (proximal promoter) (5-GGT TGG ATT TTA GGA GTA AAA and AAA ACC AAC CTT TAA AAA AAA) and set #2 (exon) (5-TAT TTG GGA AGT TGG TTG G and 5-CTC ACA TTC CCT ACC TAA AAC). The PCR products were purified and digested with BstUI or TaqI to determine the methylation status. Tsp509I was used to verify the completion of bisulfite conversion. For bisuifite sequencing, the PCR products were cloned into TOPO-TA vector (Invitrogen), and purified plasmid from five individual clones from each set were sequenced. The construction of {Delta}ATRX and {Delta}N-Dnmt3b was described earlier (16).

ChIP and ChIP-CHOP Analysis and Sequencing—ChIP assay was performed as described earlier (9, 32). Cells were cross-linked with 1% formaldehyde for 10 min followed by sonication of cell lysate that was precleared with preimmune serum for Dnmt3b or protein G-agarose A beads for Hdac2. Dnmt3b or Hdac2 associated protein-DNA complex was pulled down by anti-Dnmt3b or anti-Hdac2 antibody, respectively, followed by extensive washing. Eluted DNA was dissolved in radioimmune precipitation assay buffer and subjected to one more round of immunoprecipitation with the same antibody to minimize nonspecific pull-down. To identify Dnmt3b target genes the DNA fragments pull-down by Dnmt3b were subjected to end filling/repairing with Klenow and subsequently cloned into the SmaI site of pBlueScript-SK+ to allow blue white color selection. Individual clones were identified by automated sequencing. The identity of the potential genes was established with gene analyzing tools and gene databases (BLAST: www.ncbi.nlm.nih.gov/BLAST; BLAT: genome.ucsc.edu/cgi-bin/hgBlat; SOURCE: genome-www5.stanford.edu/cgi-bin/source/; Uniprot: www.expasy.uniprot.org/). The primers used to amplify the T-Cad promoter were 5'-AGG GAG CGT TAT GAA GGA ATCC and 5'-GAG GAG GCG AAC CAA AGT TACC. The primers used for GAPDH promoter were 5'-TCA GCG GGT GTT GTT TGT GTCC and 5'-TTT GCG TGC GTG TGT GTC TG. The primers used for PI3K promoter were TCC GCT TTT GTG GAG ATA CCG and AAC TGC TGT TGG AAG TAG TGT CCC. For CHIP-CHOP analysis, the Dnmt3b pulled down DNA, and input DNA were digested with either HpaII (methylation-sensitive) or its isoschizomer MspI (methylation-insensitive) followed by PCR analysis with the same primers.

In Vitro DNA Methylation—The protocol used for the site-specific methylation of T-Cad was as described (33).

Transient Transfection and Luciferase Assay—PC12 cells were plated at a density of 5 x 105/12-well plate, transfected with T-Cad promoter (pT-cadGL2 along with Dmt3b or empty vector using Lipofectamine 2000TM (Invitrogen). Cells were harvested 48 h post-transfection followed by the luciferase reporter assay in the cell lysate (29). Transfection of Dnmt3b siRNA was performed as described (16).

Indirect Immunofluorescence Assay—PC12 cells were plated in Lab-Tek chamber and fixed with 4% paraformaldehyde, permeabilized, and incubated in blocking buffer (1% bovine serum albumin, 10% goat serum) for 1 h, followed by primary antibody overnight at 4 °C. Subsequently the cells were incubated with TRITC-conjugated secondary antibody (for M2 antibody), mounted in 4',6-diamidino-2-phenylindole containing mounting medium, and visualized under immunofluorescence microscopy.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
T-Cad Is a Dnmt3b Target Gene in PC12 Cells—To explore the molecular mechanism of Dnmt3b-mediated differentiation of PC12 cells, we identified the potential targets in these cells. For this purpose, the Dnmt3b-DNA complex was immunoprecipitated with Dnmt3b antibody and the purified DNA was cloned into pBSK+. Approximately 120 clones were sequenced. The identity of the potential target genes was established by data base analysis. Based on their known or postulated function, Dnmt3b target genes were classified into five categories, namely, cell matrix/transmembrane proteins, proteins specific to brain/neuron, signaling transduction, cell cycle progression, and transcriptional regulation (see supplemental Table S1). Approximately 10% of the pulled down sequences were ALU repeats, single repeats, or long terminal repeats (not listed).

We selected one of the target genes, T-Cad, for further study based on the important role of the encoded protein in cell-cell adhesion, cell signaling, embryogenesis, and in motor neuron axon growth (20, 17, 34). The association of Dnmt3b with T-Cad promoter in PC12 cells was verified by chromatin immunoprecipitation followed by PCR analysis. T-Cad promoter was specifically amplified from the DNA immunoprecipitated with Dnmt3b antibody but not from the DNA pulled down from preimmune serum. The result showed that Dnmt3b was indeed associated with T-Cad promoter (Fig. 1A). Furthermore, the lack of association of Dnmt3b with the GAPDH promoter, a housekeeping gene, confirmed its specific association with T-Cad promoter (Fig. 1A).

Depletion of Dnmt3b Up-regulates T-Cad Expression in PC12 Cells— To elucidate the functional significance of the association of Dnmt3b with T-Cad promoter, T-Cad expression was measured in PC12 cells depleted of Dnmt3b by antisense RNA (16). Real-time RT-PCR analysis showed that the mRNA level of T-Cad was elevated 3-fold in Dnmt3b depleted cells (Dnmt3bAS) (Fig. 1B, upper panel) compared with the vector-transfected cells (p < 0.01). Western blot analysis demonstrated significant depletion of Dnmt3b in cells expressing antisense 3b (Fig. 1B, lower panel). T-Cad mRNA was also up-regulated in cells depleted of Dnmt3b using siRNA (Fig. 1C, top panel). The level of T-Cad 48h post-transfection increased proportionately (~2-fold) with the concentration of Dnmt3b siRNA used, whereas the same amount of scrambled siRNA did not have any significant effect. The increase in T-Cad mRNA level after 72 h was less pronounced (Fig. 1C, top panel), which is consistent with the increase in Dnmt3b mRNA (Fig. 1C, middle panel) probably due to decrease in intracellular siRNA level with time. No significant alteration in Dnmt3b protein level was detected in scramble siRNA transfected cells compared with that of the parental cells whereas its level was reduced by 75% in Dnmt3b-siRNA transfected cells (Fig. 1C, bottom panel). Western blot analysis showed that T-Cad protein level significantly increased upon Dnmt3b depletion in PC12 cells (Fig. 1D) that correlated with increase in its mRNA level (Fig. 1, B and C). These results demonstrate that Dnmt3b negatively regulates T-Cad expression. Dnmt3b level was not altered in vector-transfected cells compared with that of parental cells (data not shown).


Figure 1
View larger version (43K):
[in this window]
[in a new window]
  		FIGURE 1.
Dnmt3b represses T-Cad expression. A, association of Dnmt3b with the T-Cad promoter. ChIP assay was performed with PC12 cells using Dnmt3b-specific antibody, followed by PCR amplification of T-Cad and GAPDH promoters. Chromatin (Input) and DNA precipitated with preimmune serum were used as positive and negative controls, respectively. GAPDH promoter was amplified from input DNA only demonstrating specific pull-down of T-Cad by Dnmt3b antibody. B, up-regulation of T-Cad mRNA in PC12 cells expressing antisense Dnmt3b. Real-time quantitative RT-PCR was used to analyze T-Cad mRNA expression in PC12 cells expressing antisense Dnmt3b (Dnmt3bAS) or vector-transfected cells (V). Dnmt3b protein level was measured by Western blot analysis with Dnmt3b antibody. Ku-70 was used as loading control. C, up-regulation of T-Cad mRNA upon Dnmt3b depletion using siRNA. PC12 cells were transfected with different concentrations of Dnmt3b specific siRNA or scrambled siRNA (SC) that has no homology to any coding region for 48 and 72 h. RNA isolated from Dnmt3b siRNA-transfected cells as well as untransfected cells was used for real-time quantitative RT-PCR analysis (top panel). mRNA expression of Dnmt3b in Dnmt3b siRNA-transfected cells was analyzed by RT-PCR analysis (middle panel). Whole cell extracts from parental (P)-, scrambled siRNA (Sc, 40 nM)-, and Dnmt3b siRNA (si, 40 nM)-transfected PC12 cells were used for Western blot analysis with Dnmt3b and Ku-70 antibodies (bottom panel). D, T-Cad protein is elevated in Dnmt3b antisense (Dnmt3bAS) cells. Whole cell extract was prepared from Dnmt3bAS and vector-transected cells by Western blot analysis with T-Cad, Dnmt3b, and Ku-70 antibodies.

 
T-cadherin CGI Is Partially Methylated in PC12 Cells, Which Is Not Significantly Altered upon Dnmt3b Depletion—To identify the underlying mechanism of Dnmt3b-mediated down-regulation of T-Cad expression, we first investigated whether Dnmt3b regulates the methylation status of T-Cad promoter in PC12 cells. To address this issue, we performed COBRA (combined bisulfite-restriction analysis) of T-cad promoter CGI in the vector-transfected and Dnmt3b depleted PC12 cells. Bisulfite treatment of DNA converts unmethylated cytosines to uracils, whereas methylated cytosines remain unaffected. Upon subsequent PCR, uracils and methylcytosines are amplified as thymine and cytosines, respectively. The amplified PCR product from only methylated DNA could be digested by enzymes such as TaqI (TCGA) or BstUI (CGCG) due to retention of cytosine. The PCR products obtained from two regions of the T-Cad CGI spanning the proximal promoter (-220 to -38) and first exon (-38 to +96) (Fig. 2A) were digested with these enzymes. The results showed that the promoter was partially digested with these enzymes demonstrating partial methylation (Fig. 2B, left and middle panels). The methylation of proximal promoter was significantly less (~20%) than that of exon 1 (~40%) (Fig. 2B, left and middle panels). Complete digestion of the PCR products with Tsp509I confirmed complete bisulfite conversion (Fig. 2B, right panel). It is noteworthy that the extent of digestion of the PCR product obtained from Dnmt3b-depleted cells with BstUI (Fig. 2B, left panel) or TaqI (Fig. 2B, middle panel) was comparable with that of vector-transfected cells. To determine the methylation profile of individual CpG base pairs within the CGI of T-Cad, bisulfite genomic sequencing was performed (Fig. 2C). The sequence analysis revealed sparse methylation of CpGs in the proximal promoter region and comparatively dense methylation of CpGs in the exon 1 in both Dnmt3b-depleted cells and vector-transfected control cells (Fig. 2C), which corroborated the COBRA data (Fig. 2B). These results suggest that T-Cad CGI is not heavily methylated in PC12 cells, which is maintained in the absence of Dnmt3b probably by Dnmt1 and/or Dnmt3a.


Figure 2
View larger version (45K):
[in this window]
[in a new window]
  		FIGURE 2.
Methylation status of the CGI located on T-Cad promoter and exon 1 is not significantly altered upon Dnmt3b depletion. A, schematic diagram showing the distribution of CpGs on T-Cad (T-Cad) promoter and exon 1 CGI. The bar represents CpG dinucleotides. The diamond, oval, and open arrows represent BstUI, TaqI, and Tsp509I sites, respectively, in bisulfite-converted T-Cad DNA. +1 indicates the transcription start site. Arrows with solid and broken lines represent the primers used spanning the proximal promoter and exon 1, respectively. B, COBRA of T-Cad CGI. Genomic DNA isolated from Dnmt3b antisense cells (Dnmt3bAS) and vector-transfected control cells was treated with bisulfite reagent, amplified with T-Cad-specific primers with no CpG bias, followed by digestion with BstUI, TaqI, or Tsp509I. Products were separated on an agarose gel, visualized after staining with ethidium bromide, and quantified with Kodak imaging software. Left panel, PCR products spanning proximal promoter of T-Cad were digested with BstUI. Middle panel, TaqI digestion of the PCR product spanning exon 1. Right panel, Tsp509I digestion of T-Cad promoter and exon 1. C, bisulfite genomic sequencing analysis of T-Cad promoter in Dnmt3b-depleted cells (Dnmt3bAS) and vector-transfected PC12 cells (vector). PCR products from B.1 and B.2 were cloned with TA-vector and sequenced. The open square and filled square represent unmethylated and methylated cytosine, respectively. The positions of the CpGs are labeled on top of each box.

 
Partial methylation of T-Cad promoter raised the question whether Dnmt3b is preferentially associated with the methylated promoter. To address this issue ChIP-CHOP assay was performed. DNA pulled down with preimmune sera or Dnmt3b antibodies was either undigested or digested with HpaII or MspI. The input DNA was digested in parallel. An aliquot of the digested DNA was amplified with primers spanning the HpaII/MspI site on the CGI. The amount of PCR product from HpaII-digested DNA (methylated promoter) was 40% of that obtained from the undigested DNA (both methylated and unmethylated promoter) pulled down by Dnmt3b antibody (Fig. 3, B and C). These data suggest that Dnmt3b is associated with both methylated and unmethylated T-Cad promoter. Absence of PCR product from the DNA precipitated by preimmune sera and lack of amplification of GAPDH promoter showed the specificity of this assay (Fig. 3B).

PWWP and ATRX Domains of Dnmt3b Mediate Its Inhibitory Activity on the T-Cad Promoter—Since Dnmt3b is associated with T-Cad promoter irrespective of its methylation status, it was important to determine whether it regulates activity of both promoters. To test this possibility, T-Cad promoter was amplified from PC12 genomic DNA and cloned into luciferase reporter vector (pT-cadGL2). The cloned T-Cad promoter encompasses two HpaII sites, which were in vitro methylated with HpaII methylase to generate methylated promoter. Mock-methylated or HpaII-methylated T-Cad promoter was co-transfected with the wild type or different mutants of Dnmt3b (Fig. 4A). The T-Cad promoter-driven luciferase activity was significantly impeded (~50%) when the promoter was methylated at HpaII sites (Fig. 4B, upper panel, lanes 1 and 4). Ectopic expression of Dnmt3b further inhibited the activity of the promoter irrespective of its methylation status (lanes 2 and 5). The extent of inhibition of Dnmt3b on both promoters was comparable (55 and 58% on mock-methylated and methylated promoters, respectively). It is noteworthy that the inhibitory effect of the catalytic site (CS) mutant of Dnmt3b on both T-Cad promoters was similar (~60%) to that of the wild type protein (lanes 3 and 6). The level of the ectopic wild type and CS mutant Dnmt3b was also comparable (Fig. 4B, lower panel). These results indicate that Dnmt3b suppresses T-Cad promoter activity irrespective of its methylation status and its catalytic activity is not required for this process. Furthermore, the extent of repression of T-Cad promoter activity increased with increasing amount of transfected Dnmt3b expression vector (Fig. 4C).


Figure 3
View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 3.
Dnmt3b is associated with both unmethylated and methylated T-Cad promoter as revealed by ChIP-ChOP assay. A, schematic depiction of ChIP-CHOP assay. Formaldehyde cross-linked DNA (Input) or Dnmt3b antibody pulled down DNA was digested with methylation-sensitive restriction enzyme HpaII (H) or methylation-insensitive enzyme MspI (M) or mock-digested (-) followed by PCR analysis with the T-Cad or GAPDH promoter-specific primers. B, ethidium bromide staining of the amplified product separated on an agarose gel. C, quantitative analysis of the association of Dnmt3b with the T-Cad promoters as assessed by the ratio of HpaII-resistant product to input PCR product.

 


Figure 4
View larger version (45K):
[in this window]
[in a new window]
  		FIGURE 4.
Dnmt3b inhibits T-Cad promoter activity irrespective of its methylation status. A, schematic diagram of Dnmt3b wild type and different mutant variants used in this study. B, Dnmt3b represses T-Cad promoter activity independent of its catalytic domain. Upper panel, transient transfection. T-Cad promoter was cloned into pGL2 reporter vector (pT-cadGL2). Unmethylated (Mock) or HpaII methylase-methylated pT-cadGl2 (HpaII-methylated) was co-transfected with the wild type (WT), catalytic domain mutant (CS) of Dnmt3b or control vector (pcDNA) into PC12 cells, followed by luciferase reporter assay. Each transfection was performed in triplicate and normalized to the cell number in each transfection assay. Lower panel, ectopic expression of wild type (WT) or CS of Dnmt3b was verified by Western blot analysis. Ku-70 was used as loading control. We could not use pRL-tk as internal control, since Dnmt3b affected its activity. C, inhibitory effect of Dnmt3b on T-Cad promoter is proportional to increasing amount of transfected Dnmt3b. The transfection procedure was as described above. D, transfected T-Cad promoter is not de novo methylated in PC12 cells. PC12 cells were transfected with pT-cadGl2 along with either empty vector or Dnmt3b. pT-cadGl2 was isolated 48 h post-transfection and digested either with HpaII or MspI or Aci I, followed by PCR analysis. E, deletion of ATRX or PWWP domain of Dnmt3b partially ablates its repressive effect on the T-Cad promoter. Upper panel: unmethylated (Mock) or HpaII methylase pT-cadGL2 (HpaII-methylated) was co-transfected with Dnmt3b wild type Dnmt3b-FLAG (WT), ATRX domain deletion mutant ({Delta}ATRX), or PWWP domain mutant ({Delta}PWWP) or control vector (pCMV) into PC12 cells, followed by luciferase reporter assay. Each transfection was performed in triplicate and normalized to the cell number used in each transfection assay. Lower panel, ectopic expression of WT or different mutant of Dnmt3b was verified by Western blot analysis with anti-FLAG antibody. NS denotes nonspecific band demonstrating equal loading of proteins. F, N-terminal deletion mutant of Dnmt3b had no inhibitory effect on the promoter activity. Upper panel, co-transfection of T-Cad promoter (pT-CadGL2) with Dnmt3b wild type Dnmt3b-FLAG (WT), N-terminal domains deletion mutant ({Delta}N, amino acids 1-528), or the control vector (pCMV) were as described above. Lower panel, ectopic expression of wild type (WT) or {Delta}N-Dnmt3b was verified by Western blot analysis with anti-FLAG antibody.

 
To determine whether the transfected T-Cad promoter is methylated de novo upon ectopic expression of Dnmt3b, the reporter plasmid (pT-cadGL2) was isolated from PC12 cells co-transfected with Dnmt3b expression vector or the corresponding empty vector. The plasmid DNA was subjected to digestion with methylation sensitive restriction enzyme HpaII, AciI, or methylation-insensitive MspI, followed by PCR analysis with T-Cad-specific forward primer and pGL2 specific reverse primer. Lack of amplification of the T-Cad promoter fragment from HpaII- or AciI-digested plasmid DNA showed that the promoter was not methylated when co-expressed with Dnmt3b or empty vector (Fig. 4D). These results further prove that the Dnmt3b-mediated suppression of T-Cad promoter activity does not involve promoter methylation. Furthermore, inability of 5-azacytidine to increase basal expression of the endogenous and transfected T-Cad promoter (data not shown) supports the notion that methylation does not regulate its expression in PC12 cells, although its promoter is sparsely methylated (Fig. 2C).


Figure 5
View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 5.
Association of Hdac2 with T-Cad promoter. A, ChIP assay was performed with PC12 cells using Hdac2 specific antibody, followed by PCR amplification of T-Cad and PI3K promoters. Chromatin (Input) and DNA precipitated with protein G-agarose beads (-Ab) were used as positive and negative controls, respectively. B, up-regulation of T-Cad mRNA upon TSA treatment. Total RNA isolated from PC12 cells either untreated or treated with 3 nM TSA for 18 h was subjected to real-time RT-PCR analysis. C, TSA treatment releases T-Cad promoter from Dnmt3b-mediated repression. PC12 cells were transfected with pT-cadGL2 along with Dnmt3b or vector (pCMV) and after 24 h cells were either left untreated or treated with 3 nM TSA for an additional 18 h. Cell lysate was subjected to luciferase reporter assay. Each transfection was performed in triplicate and normalized to the cell number from each transfection.

 
Apart from the catalytic domain, Dnmt3b harbors a relatively larger N-terminal region that encompasses PWWP and ATRX domains (Fig. 4A). Although PWWP domain of Dnmt3b exhibits DNA binding property (35), Dnmt3b can still binds to DNA in its absence (36). It is also involved in protein-protein interaction (37, 38). The ATRX domain is homologous to the ATRX gene, a member of the SWI/SNF family of chromatin remodeling proteins (39). ATRX domain can recruit histone deacetylases (Hdacs) and other transcriptional co-repressors to inhibit gene expression (40, 41). To investigate the potential involvement of these domains in the repressor function of Dnmt3b, pT-cadGL2 was co-transfected with {Delta}ATRX or {Delta}PWWP mutants. The inhibitory effect of Dnmt3b on the promoter activity was partially recovered upon deletion of PWWP or ATRX domain (Fig. 4E, inhibition of mock-methylated promoter was 61 and 37%, respectively, versus 79% by the wild type; methylated promoter was 42 and 30%, respectively, versus 58% by the wild type). Western blot analysis demonstrated comparable expression of Dnmt3b variants (Fig. 4, B and E). The partial reversal of its inhibitory effect on T-Cad promoter upon deletion of these domains suggests that both PWWP and ATRX domain are essential for the repressor function of Dnmt3b on T-Cad promoter irrespective of its methylation status. These results were further confirmed by ectopic expression of the entire N-terminal deletion mutant of Dnmt3b ({Delta}N), where its inhibitory effect on T-Cad promoter was abolished (Fig. 4F). The inhibitory effect of Dnmt3b on T-Cad promoter varied slightly between experiments (Fig. 4, B and E), which was possibly due to differential expression of Dnmt3b.

Hdac2 Is Associated with T-Cad Promoter, and the Inhibitory Activity of Dnmt3b on the Promoter Can Be Relieved by Treatment with TSA, a Hdac Inhibitor—The involvement of ATRX domain of Dnmt3b in the repression of T-Cad suggested to us the potential involvement of Hdac as a co-repressor. Our earlier study demonstrated Dnmt3b physically and functionally interact with Hdac2 in PC12 cells differentiated by NGF (16). To investigate whether Hdac2 plays a role in the regulation of the expression of T-Cad, we performed ChIP assay with Hdac2 specific antibody. Indeed, Hdac2 was associated with T-Cad promoter (Fig. 5A, upper panel, lane 3). No PCR product was detected when protein G-agarose beads alone were used for the assay (lane 2). Lack of amplification of PI3K promoter further showed the specificity of this association (Fig. 5A, lower panel). Next, we measured T-Cad mRNA level in cells treated with TSA. The result showed dramatic increase (~25-fold) in T-Cad mRNA upon treatment with TSA (Fig. 5B). Similarly, TSA treatment also activated the trasfected promoter by 4.5-fold (Fig. 5C) suggesting that Hdacs also regulate the activity of the promoter. Significantly less activation of the ectopic promoter compared with that of the mRNA level is probably due to the availability of a small fraction of the transfected promoter in the nucleosomal structure. Alternatively, the transfected promoter (~1.6 kb) cannot execute full function due to lack of some regulatory elements. However, the results demonstrate that both endogenous and the transfected promoters are regulated by Hdacs. The next obvious question was whether Dnmt3b repressed T-Cad by recruiting Hdac. A 7.6-fold increase in T-Cad promoter activity in Dnmt3b transfected cells upon TSA treatment showed that suppression of histone deacetylatase activity could overcome the inhibitory activity of Dnmt3b on the promoter (Fig. 5C). This result suggests that the recruitment of Hdac(s), probably Hdac2, by Dnmt3b is essential to repress the T-Cad promoter.


Figure 6
View larger version (106K):
[in this window]
[in a new window]
  		FIGURE 6.
T-Cad inhibits NGF-induced neurite outgrowth in PC12 cells. A, Western blot analysis with anti-FLAG antibody of PC12 cells stably expressing FLAG-tagged T-Cad (T-Cad). NS, nonspecific to show equal loading. B, morphology of PC12 cells differentially expressing T-Cad (T-Cad1 and T-Cad2) as well as vector-transfected cells (Vector) treated with NGF (50 ng/ml) for different time periods. Cells bearing neurites at least two-cell body in length were counted at day 6 of NGF treatment. At least 200 cells were counted in each sample. Cell morphology was captured by digital photography under phase contrast microscopy. C, representative image of PC12 cells before and after NGF treatment. Bar, 100 µm.

 
T-Cad Inhibits NGF-induced Neurite Outgrowth in PC12 Cells—To investigate the potential role of T-Cad in NGF-induced PC12 cell differentiation, stable cell lines constitutively expressing FLAG-tagged T-Cad (T-CadFLAG) were generated. Two cell lines expressing low (T-Cad1) and high (T-Cad2) levels of T-Cad (Fig. 6A) were used for further studies. First, the neuronal differentiation was examined in these cells treated with NGF for up to 6 days and compared with that of vector-transfected (control) cells. Neurite outgrowth was visible within 24 to 48 h of NGF treatment in control cells (Fig. 6A). In contrast, both T-Cad1 and T-Cad2 cells exhibited a tendency to grow in clusters and responded poorly to NGF treatment (Fig. 6, B and C). After prolonged NGF exposure, neurite outgrowth was observed only at the periphery of the clusters in T-Cad-expressing cells, and the extent of neurite formation was inversely correlated with the level of T-Cad expression (Fig. 6, B and C). Thus, T-Cad1 cells (low T-Cad level) exhibited twice as much neurite outgrowth as T-Cad2 cells (high T-Cad level) (Fig. 6, B and C) after 6 days of NGF exposure. This result suggests that T-Cad impedes NGF-induced neurite outgrowth.


Figure 7
View larger version (48K):
[in this window]
[in a new window]
  		FIGURE 7.
T-Cad redistribution occurs concomitantly with NGF treatment. T-Cad-expressing PC12 cells either untreated or treated with NGF for 24-96 h were stained with anti-FLAG M2 antibody (to detect FLAG-tagged T-Cad, red) and 4',6-diamidino-2-phenylindole (DAPI) (to locate the nucleus, blue) and visualized under fluorescence microscope. The arrow indicates strong staining of T-Cad.

 
T-Cad Is Redistributed from Cell-Cell Contact Region to Neurite Growth Cones in Differentiated Cells—T-Cad is predominantly an extracellular protein associated with the plasma membrane through GPI anchor. Because NGF-induced differentiation of PC12 cells causes profound changes on the plasma membrane that include membrane depolarization (42) and translocation or redistribution of membrane-bond signaling molecules such as TrkA (43), PKC{alpha} (44), and inositol polyphosphate 5-phosphatase (PIPP) (45), we examined the localization of T-Cad after NGF treatment. T-Cad exhibited punctate staining at the plasma membrane and dense staining was observed at cell-cell contact in untreated cells (Fig. 7, A and C), which indicated its concentration at the cell-cell contact points. Strikingly, T-Cad was redistributed upon NGF treatment as demonstrated by its localization at neurite growth cones and growing axon processes (Fig. 7, D and F, G and I, and J and L). The redistribution of T-Cad to growth cone in response to NGF might have a role in its inhibition of neurite outgrowth in PC12 cells.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
The present study explored the role of T-Cad in neuronal differentiation using NGF-mediated neurite outgrowth in PC12 cells as the model system. Specific increase in Dnmt3b level, one of the three functional DNA methyltransferases, reported in our earlier study (16) and the present observation that T-Cad is one of the Dnmt3b target genes prompted us to explore the functional significance of this finding. Interestingly, Dnmt3b suppressed T-Cad expression with no significant effect on its promoter methylation. Furthermore, depletion of Dnmt3b from PC12 cells enhanced its expression, which correlated with continued proliferation of the cells in the presence of NGF (16). This result reinforces the notion that T-Cad functions as a negative signal in neuronal differentiation. In this context, it is noteworthy that T-Cad functions in initiating proliferation in vascular cells and that it may facilitate progression of proliferative vascular disorders (46). There are also indications that human T-Cad is involved in lung metastasis of osteosarcomas (47). The abundant expression of T-Cad in undifferentiated or metastatic cancer cells is consistent with the lack of or markedly reduced expression of T-Cad in differentiated sympathetic neurons in vivo (20) and in differentiated PC12 cells observed in the present study.

The molecular mechanism underlining T-Cad-mediated inhibition of neurite outgrowth remains to be resolved. It appears that it can function as a negative regulator of axon growth. It is expressed in the region devoid of extending growing motor axons during chick embryo hind limb projection, which implicates that T-Cad functions as an inhibitory factor for motor axon growth (48). The present study showed re-distribution of T-Cad during NGF-induced differentiation of PC12 cells as shown by its strong staining in restricted membrane region and growing axon processes after NGF treatment in contrast to dense staining at cell-cell contact region. This observation together with the finding that its overexpression inhibits neurite outgrowth suggests that T-Cad functions as a negative navigator for axon guidance during NGF-induced neuronal differentiation. The high level of T-Cad in the cerebral cortex, medulla oblongata, and nucleus olivaris relative to its absence from granular cells (19) suggests that it may play an important role in specific neural growth. Exploration of its regulation will help us understand its function.

The suppression of T-Cad by Dnmt3b independent of its enzymatic function merits discussion. All DNA methyltransferases consist of the catalytic domain at their C termini and a transcription repressor domain at their N termini. Through their N-terminal domains, Dnmts transcriptionally repress gene expression by recruiting transcriptional co-repressors and chromatin remodeling enzymes in a methylation independent manner (5, 41, 49, 50). Dnmt3L, a Dnmt3 family member devoid of intrinsic DNA methyltransferase activity due to lack of the catalytic motif, can also function as a transcriptional repressor (51). Although T-Cad is a Dnmt3b target gene its promoter region is sparsely methylated (Fig. 2), and its expression is not induced after treatment of the differentiated PC12 cells with the potent DNA hypomethylating agent, 5-AzaC (data not shown). The lack of requirement of the catalytic activity of Dnmt3b in T-Cad promoter repression further reinforces the notion that Dnmt3b regulates expression of this gene by methylation independent mechanisms. Restoration of T-Cad expression by an Hdac inhibitor suggests that histone deacetylation plays a significant role in its suppression. Since genes suppressed by methylation are not re-activated by Hdac inhibitors in the absence of a DNA hypomethylating agent (9, 52), up-regulation of T-Cad expression by TSA alone further proves the concept that suppression of the cadherin protein by Dnmt3b in PC12 cells is independent of its DNA methyltransferase activity.

Finally, the specific function of T-Cad deserves comments. The present study established it as a possible negative regulator of axon growth in neuronal differentiation. T-Cad expression is enhanced in some cancers such as metastatic lung cancer (47), whereas its expression is significantly down-regulated in other cancers like colorectal cancer, breast cancer, and skin cancers, probably mediated by promoter methylation (53-56). It would be of interest to investigate its role in brain tumorigenesis. Nevertheless, these findings have demonstrated an important role of T-Cad in altering the differentiated state that contributes to cancer and has provided the impetus to explore the molecular mechanism of T-Cad signaling as well as regulation of its expression.


   FOOTNOTES
 
* This work was supported in part by Grants ES 10874, and CA 86978 (to S. T. J.), from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Table S1. Back

1 To whom correspondence should be addressed: Dept. of Molecular and Cellular Biochemistry, College of Medicine, Ohio State University, 333 Hamilton Hall, 1645 Neil Ave., Columbus, OH 43210. Tel.: 614-688-5494; Fax: 614-688-5600; E-mail: jacob.42{at}osu.edu.

2 The abbreviations used are: Dnmt, DNA methyltransferase; CGI, CpG island; Hdac, histone deacetylase; T-Cad, T-cadherin; COBRA, combined bisulfite restrict analysis; ChIP, chromatin immunoprecipitation; PI3K, phosphatidylinositol 3-kinase; TSA, trichostatin A; siRNA, small interfering RNA; NGF, nerve growth factor; RT, reverse transcription; TRITC, tetramethylrhodamine isothiocyanate; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Back


   ACKNOWLEDGMENTS
 
We thank Drs. Chih-Lin Hsieh for providing cDNAs for the wild type and catalytic domain mutant of Dnmt3b, En Li for Dnmt3b cDNA, and Sarmila Majmuder and Tasneem Motiwala for critically reading the manuscript.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Goll, M. G., and Bestor, T. H. (2005) Annu. Rev. Biochem. 74, 481-514[CrossRef][Medline] [Order article via Infotrieve]
  2. Hermann, A., Gowher, H., and Jeltsch, A. (2004) Cell. Mol. Life Sci. 61, 2571-2587[CrossRef][Medline] [Order article via Infotrieve]
  3. Li, E., Bestor, T. H., and Jaenisch, R. (1992) Cell 69, 915-926[CrossRef][Medline] [Order article via Infotrieve]
  4. Okano, M., Bell, D. W., Haber, D. A., and Li, E. (1999) Cell 99, 247-257[CrossRef][Medline] [Order article via Infotrieve]
  5. Datta, J., Majumder, S., Bai, S., Ghoshal, K., Kutay, H., Smith, D. S., CraBB, J. W., and Jacob, S. T. (2005) Cancer Res. 65, 10891-10900[Abstract/Free Full Text]
  6. Fuks, F., Burgers, W. A., Brehm, A., Hughes-Davies, L., and Kouzarides, T. (2000) Nat. Genet. 24, 88-91[CrossRef][Medline] [Order article via Infotrieve]
  7. Fuks, F., Hurd, P. J., Wolf, D., Nan, X., Bird, A. P., and Kouzarides, T. (2003) J. Biol. Chem. 278, 4035-4040[Abstract/Free Full Text]
  8. Geiman, T. M., and Robertson, K. D. (2002) J. Cell Biochem. 87, 117-125[CrossRef][Medline] [Order article via Infotrieve]
  9. Ghoshal, K., Datta, J., Majumder, S., Bai, S., Dong, X., Parthun, M., and Jacob, S. T. (2002) Mol. Cell. Biol. 22, 8302-8319[Abstract/Free Full Text]
  10. Baylin, S. B., Esteller, M., Rountree, M. R., Bachman, K. E., Schuebel, K., and Herman, J. G. (2001) Hum. Mol. Genet. 10, 687-692[Abstract/Free Full Text]
  11. Esteller, M. (2005) J. Pathol. 205, 172-180[CrossRef][Medline] [Order article via Infotrieve]
  12. Herman, J. G., and Baylin, S. B. (2000) Curr. Top. Microbiol. Immunol. 249, 35-54[Medline] [Order article via Infotrieve]
  13. Motiwala, T., Ghoshal, K., Das, A., Majumder, S., Weichenhan, D., Wu, Y. Z., Holman, K., James, S. J., Jacob, S. T., and Plass, C. (2003) Oncogene 22, 6319-6331[CrossRef][Medline] [Order article via Infotrieve]
  14. Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., and Issa, J. P. (1998) Adv. Cancer Res. 72, 141-196[Medline] [Order article via Infotrieve]
  15. Robertson, K. D., and Jones, P. A. (2000) Carcinogenesis 21, 461-467[Abstract/Free Full Text]
  16. Bai, S., Ghoshal, K., Datta, J., Majumder, S., Yoon, S. O., and Jacob, S. T. (2005) Mol. Cell. Biol. 25, 751-766[Abstract/Free Full Text]
  17. Takeuchi, T., and Ohtsuki, Y. (2001) Histol. Histopathol. 16, 1287-1293[Medline] [Order article via Infotrieve]
  18. Ranscht, B., and Bronner-Fraser, M. (1991) Development (Camb.) 111, 15-22[Abstract]
  19. Takeuchi, T., Misaki, A., Liang, S. B., Tachibana, A., Hayashi, N., Sonobe, H., and Ohtsuki, Y. (2000) J. Neurochem. 74, 1489-1497[CrossRef][Medline] [Order article via Infotrieve]
  20. Fredette, B. J., Miller, J., and Ranscht, B. (1996) Development (Camb.) 122, 3163-3171[Abstract]
  21. Hibi, K., Kodera, Y., Ito, K., Akiyama, S., and Nakao, A. (2004) Br. J. Cancer 91, 1139-1142[Medline] [Order article via Infotrieve]
  22. Takeuchi, T., Liang, S. B., and Ohtsuki, Y. (2002) Mol. Carcinog. 35, 173-179[Medline] [Order article via Infotrieve]
  23. Sato, M., Mori, Y., Sakurada, A., Fujimura, S., and Horii, A. (1998) Hum. Genet. 103, 96-101[CrossRef][Medline] [Order article via Infotrieve]
  24. Widschwendter, A., Ivarsson, L., Blassnig, A., Muller, H. M., Fiegl, H., Wiedemair, A., Muller-Holzner, E., Goebel, G., Marth, C., and Widschwendter, M. (2004) Int. J. Cancer 109, 163-166[CrossRef][Medline] [Order article via Infotrieve]
  25. Philippova, M. P., Bochkov, V. N., Stambolsky, D. V., Tkachuk, V. A., and Resink, T. J. (1998) FEBS Lett. 429, 207-210[CrossRef][Medline] [Order article via Infotrieve]
  26. Hug, C., Wang, J., Ahmad, N. S., Bogan, J. S., Tsao, T. S., and Lodish, H. F. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 10308-10313[Abstract/Free Full Text]
  27. Tkachuk, V. A., Bochkov, V. N., Philippova, M. P., Stambolsky, D. V., Kuzmenko, E. S., Sidorova, M. V., Molokoedov, A. S., Spirov, V. G., and Resink, T. J. (1998) FEBS Lett. 421, 208-212[CrossRef][Medline] [Order article via Infotrieve]
  28. Kuzmenko, Y. S., Kern, F., Bochkov, V. N., Tkachuk, V. A., and Resink, T. J. (1998) FEBS Lett. 434, 183-187[CrossRef][Medline] [Order article via Infotrieve]
  29. Majumder, S., Ghoshal, K., Datta, J., Bai, S., Dong, X., Quan, N., Plass, C., and Jacob, S. T. (2002) J. Biol. Chem. 277, 16048-16058[Abstract/Free Full Text]
  30. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[Medline] [Order article via Infotrieve]
  31. Ghoshal, K., Majumder, S., and Jacob, S. T. (2002) Methods Enzymol. 353, 476-486[Medline] [Order article via Infotrieve]
  32. Weinstein, L. S. (2001) Biol. Psychiatry 50, 927-931[CrossRef][Medline] [Order article via Infotrieve]
  33. Ghoshal, K., Majumder, S., Datta, J., Motiwala, T., Bai, S., Sharma, S. M., Frankel, W., and Jacob, S. T. (2004) J. Biol. Chem. 279, 6783-6793[Abstract/Free Full Text]
  34. Angst, B. D., Marcozzi, C., and Magee, A. I. (2001) J. Cell Sci. 114, 629-641[Abstract]
  35. Ge, Y. Z., Pu, M. T., Gowher, H., Wu, H. P., Ding, J. P., Jeltsch, A., and Xu, G. L. (2004) J. Biol. Chem. 279, 25447-25454[Abstract/Free Full Text]
  36. Qiu, C., Sawada, K., Zhang, X., and Cheng, X. (2002) Nat. Struct. Biol. 9, 217-224[Medline] [Order article via Infotrieve]
  37. Shirohzu, H., Kubota, T., Kumazawa, A., Sado, T., Chijiwa, T., Inagaki, K., Suetake, I., Tajima, S., Wakui, K., Miki, Y., Hayashi, M., Fukushima, Y., and Sasaki, H. (2002) Am. J. Med. Genet. 112, 31-37[CrossRef][Medline] [Order article via Infotrieve]
  38. Stec, I., Nagl, S. B., van Ommen, G. J., and den Dunnen, J. T. (2000) FEBS Lett. 473, 1-5[CrossRef][Medline] [Order article via Infotrieve]
  39. Gibbons, R. J., McDowell, T. L., Raman, S., O'Rourke, D. M., Garrick, D., Ayyub, H., and Higgs, D. R. (2000) Nat. Genet. 24, 368-371[CrossRef][Medline] [Order article via Infotrieve]
  40. Aapola, U., Liiv, I., and Peterson, P. (2002) Nucleic Acids Res. 30, 3602-3608[Abstract/Free Full Text]
  41. Fuks, F., Burgers, W. A., Godin, N., Kasai, M., and Kouzarides, T. (2001) EMBO J. 20, 2536-2544[CrossRef][Medline] [Order article via Infotrieve]
  42. Shimazu, K., Takeda, K., Yu, Z. X., Jiang, H., Liu, X. W., Nelson, P. G., and Guroff, G. (2005) J. Cell. Physiol. 203, 501-509[CrossRef][Medline] [Order article via Infotrieve]
  43. Reddy, C. V., Malinowska, K., Menhart, N., and Wang, R. (2004) Biochim. Biophys. Acta 1667, 15-25[Medline] [Order article via Infotrieve]
  44. Marin-Vicente, C., Gomez-Fernandez, J. C., and Corbalan-Garcia, S. (2005) Mol. Biol. Cell 16, 2848-2861[Abstract/Free Full Text]
  45. Ooms, L. M., Fedele, C. G., Astle, M. V., Ivetac, I., Cheung, V., Pearson, R. B., Layton, M. J., Forrai, A., Nandurkar, H. H., and Mitchell, C. A. (2005) Mol. Biol. Cell 17, 607-622[Medline] [Order article via Infotrieve]
  46. Ivanov, D., Philippova, M., Allenspach, R., Erne, P., and Resink, T. (2004) Cardiovasc. Res. 64, 132-143[Abstract/Free Full Text]
  47. Takeuchi, T., Misaki, A., Sonobe, H., Liang, S. B., and Ohtsuki, Y. (2000) Histopathology 37, 193-194[CrossRef][Medline] [Order article via Infotrieve]
  48. Fredette, B. J., and Ranscht, B. (1994) J. Neurosci. 14, 7331-7346[Abstract]
  49. Bachman, K. E., Rountree, M. R., and Baylin, S. B. (2001) J. Biol. Chem. 276, 32282-32287[Abstract/Free Full Text]
  50. Rountree, M. R., Bachman, K. E., and Baylin, S. B. (2000) Nat. Genet. 25, 269-277[CrossRef][Medline] [Order article via Infotrieve]
  51. Deplus, R., Brenner, C., Burgers, W. A., Putmans, P., Kouzarides, T., de Launoit, Y., and Fuks, F. (2002) Nucleic Acids Res. 30, 3831-3838[Abstract/Free Full Text]
  52. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., and Baylin, S. B. (1999) Nat. Genet. 21, 103-107[CrossRef][Medline] [Order article via Infotrieve]
  53. Hibi, K., Nakayama, H., Kodera, Y., Ito, K., Akiyama, S., and Nakao, A. (2004) Br. J. Cancer 90, 1030-1033[Medline] [Order article via Infotrieve]
  54. Lee, S. W. (1996) Nat. Med. 2, 776-782[CrossRef][Medline] [Order article via Infotrieve]
  55. Takeuchi, T., Liang, S. B., Matsuyoshi, N., Zhou, S., Miyachi, Y., Sonobe, H., and Ohtsuki, Y. (2002) Lab. Invest. 82, 1023-1029[Medline] [Order article via Infotrieve]
  56. Takeuchi, T., Misaki, A., Chen, B. K., and Ohtsuki, Y. (1999) Histopathology 35, 87-88[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
S. Bai, J. Datta, S. T. Jacob, and K. Ghoshal
Treatment of PC12 Cells with Nerve Growth Factor Induces Proteasomal Degradation of T-cadherin That Requires Tyrosine Phosphorylation of Its Cadherin Domain
J. Biol. Chem., September 14, 2007; 282(37): 27171 - 27180.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
281/19/13604    most recent